73 FR 125 pgs. 36531-36533 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Good Laboratory Practice Regulations for Nonclinical Studies
Type: NOTICEVolume: 73Number: 125Pages: 36531 - 36533
Docket number: [Docket No. FDA-2008-N-0154]
FR document: [FR Doc. E8-14535 Filed 6-26-08; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0154]
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Good Laboratory Practice Regulations for Nonclinical Studies
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
DATES:
Fax written comments on the collection of information by July 28, 2008.
ADDRESSES:
To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-6974, or e-mailed to baguilar@omb.eop.gov . All comments should be identified with the OMB control number 0910-0119. Also include the FDA docket number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Berbakos, Office of the Chief Information Officer (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION:
In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
Good Laboratory Practice (GLP) Regulations for Nonclinical Studies-21 CFR Part 58 (OMB Control Number 0910-0119)-Extension
Sections 409, 505, 512, and 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 348, 355, 360(b), 360(e)) and related statues require manufacturers of food additives, human drugs and biological products, animal drugs, and medical devices to demonstrate the safety and utility of their product by submitting applications to FDA for research or marketing permits. Such applications contain, among other important items, full reports of all studies done to demonstrate product safety in man and/or other animals. In order to ensure adequate quality control for these studies and to provide an adequate degree of consumer protection, the agency issued the GLP regulations. The regulations specify minimum standards for the proper conduct of safety testing and contain sections on facilities, personnel, equipment, standard operating procedures (SOPs), test and control articles, quality assurance, protocol and conduct of a safety study, records and reports, and laboratory disqualification.
The GLP regulations contain requirements for the reporting of the results of quality assurance unit inspections, test and control article characterization, testing of mixtures of test and control articles with carriers, and an overall interpretation of nonclinical laboratory studies. The GLP regulations also contain recordkeeping requirements relating to the conduct of safety studies. Such records include the following information: (1) Personnel job descriptions and summaries of training and experience; (2) master schedules, protocols and amendments thereto, inspection reports, and SOPs; (3) equipment inspection, maintenance, calibration, and testing records; (4) documentation of feed and water analyses and animal treatments; (5) test article accountability records; and (6) study documentation and raw data.
The information collected under GLP regulations is generally gathered by testing facilities routinely engaged in conducting toxicological studies and is used as part of an application for a research or marketing permit that is voluntarily submitted to FDA by persons desiring to market new products. The facilities that collect this information are typically operated by large entities, e.g., contract laboratories, sponsors of FDA-regulated products, universities, or Government agencies. Failure to include the information in a filing to FDA would mean that agency scientific experts could not make a valid determination of product safety. FDA receives, reviews, and approves hundreds of new product applications each year based on information received. The recordkeeping requirements are necessary to document the proper conduct of a safety study, to assure the quality and integrity of the resulting final report, and to provide adequate proof of the safety of regulated products. FDA conducts onsite audits of records and reports, during its inspections of testing laboratories, to verify reliability of results submitted in applications.
The likely respondents collecting this information are contract laboratories, sponsors of FDA-regulated products, universities, or Government agencies.
In the Federal Register of March 12, 2008 (73 FR 13240), FDA published a 60-day notice requesting public comment on the information collection provisions. No comments were received.
| 21 CFR Section | No. of Respondents | Annual Frequency per Response | Total Annual Responses | Hours per Response | Total Hours | ||||
|---|---|---|---|---|---|---|---|---|---|
| 58.35(b)(7) | 300 | 60.25 | 18,075 | 1 | 18,075 | ||||
| 58.185 | 300 | 60.25 | 18,075 | 27.65 | 499,774 | ||||
| Total | 517,849 | ||||||||
| 1 There are no capital costs or operating and maintenance costs associated with this collection of information. | |||||||||
| 21 CFR Section | No. of Recordkeepers | Annual Frequency per Recordkeeping | Total Annual Records | Hours per Record | Total Hours | ||||
|---|---|---|---|---|---|---|---|---|---|
| 58.29(b) | 300 | 20 | 6,000 | .21 | 1,260 | ||||
| 58.35(b)(1) through (b)(6) and (c) | 300 | 270.76 | 81,228 | 3.36 | 272,926 | ||||
| 58.63(b) and (c) | 300 | 60 | 18,000 | .09 | 1,620 | ||||
| 58.81(a) through (c) | 300 | 301.8 | 90,540 | .14 | 12,676 | ||||
| 58.90(c) and (g) | 300 | 62.7 | 18,810 | .13 | 2,445 | ||||
| 58.105(a) and (b) | 300 | 5 | 1,500 | 11.8 | 17,700 | ||||
| 58.107(d) | 300 | 1 | 300 | 4.25 | 1,275 | ||||
| 58.113(a) | 300 | 15.33 | 4,599 | 6.8 | 31,273 | ||||
| 58.120 | 300 | 15.38 | 4,614 | 32.7 | 150,878 | ||||
| 58.195 | 300 | 251.5 | 75,450 | 3.9 | 294,255 | ||||
| Total | 786,308 | ||||||||
| 1 There are no capital costs or operating and maintenance costs associated with this collection of information. | |||||||||
Dated: June 20, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-14535 Filed 6-26-08; 8:45 am]
BILLING CODE 4160-01-S